Figure 6

Prognostic analysis in Myc^high germinal-center-B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL) and in Myc^highBcl-2^high DLBCL patients. (a and b) Among MYC-non-rearranged (MYC-R⁻) Myc^high GCB-DLBCL patients, those with Bcl-2 overexpression had significantly worse overall survival and progression-free survival compared with those who did not have Bcl-2 overexpression. (c and d) Among patients with MYC-R⁺/Myc^high GCB-DLBCL, those with Bcl-2 overexpression had significantly poorer progression-free survival compared with those who did not have Bcl-2 overexpression. The P-value for overall survival was not significant. (e and f) Among patients with Myc^highBcl-2^high GCB-DLBCL, those with MYC rearrangement had poorer overall and progression-free survival compared with those without MYC rearrangement did, but these differences were not statistically significant. (g and h) Among Myc^highBcl-2^high DLBCL patients, GCB-DLBCL patients with MYC rearrangement had significantly poorer overall and progression-free survival than Myc^highBcl-2^high patients without MYC rearrangement did. ABC, activated-B-cell-like; Bcl-2^high, high Bcl-2 protein expression; Bcl-2^low, low Bcl-2 protein expression; GCB, germinal-center-B-cell-like; Myc^high, high Myc protein expression; MYC-R⁺, MYC rearrangement-positive; MYC-R⁻, MYC rearrangement-negative.